- Home
- AFRM vs DXCM Comparison
AFRM vs DXCM Comparison
Compare AFRM & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRM | DXCM |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 28.9B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AFRM | DXCM |
|---|---|---|
| Price | $79.05 | $89.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 21 |
| Target Price | $84.52 | ★ $85.33 |
| AVG Volume (30 Days) | 3.2M | ★ 5.3M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.98 | 47.18 |
| EPS | 0.90 | ★ 1.15 |
| Revenue | ★ $3,224,412,000.00 | N/A |
| Revenue This Year | $30.78 | $14.46 |
| Revenue Next Year | $23.95 | $12.31 |
| P/E Ratio | $87.00 | ★ $79.57 |
| Revenue Growth | ★ 38.80 | N/A |
| 52 Week Low | $42.10 | $54.11 |
| 52 Week High | $100.00 | $91.62 |
Technical Indicators
Market Signals| Indicator | AFRM | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 67.69 |
| Support Level | $71.24 | $62.65 |
| Resistance Level | $79.79 | N/A |
| Average True Range (ATR) | 3.44 | 2.74 |
| MACD | 0.36 | 0.94 |
| Stochastic Oscillator | 82.44 | 88.64 |
Price Performance
Historical ComparisonAbout AFRM Affirm Holdings Inc.
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.